News

Medicaid expansion brings coverage to more diabetes patients

View on the News

Data needed on Medicaid expansion effect on outcomes

The data demonstrate the benefits of Medicaid expansion, yet nearly half of our states have chosen not to expand this benefit to their citizens. The real-world benefits and costs of Medicaid expansion merit additional research and civil debate. And perhaps, most important, their results should be used to guide health policy to address the growing burden of chronic disease.

Dr. William Herman is professor of internal medicine at the University of Michigan; Dr. William Cefalu is executive director of the Pennington Biomedical Research Center at Louisiana State University in Baton Rouge, La. Their views are taken from an editorial accompanying the study (Diabetes Care 2015 March 23 [doi: 10.2337/dc15-0348]).


 

FROM DIABETES CARE

References

More new diabetes patients are being diagnosed in states that have expanded their Medicaid programs under the Affordable Care Act, compared with states that chose not to expand, according to a study published online March 23 in Diabetes Care.

Dr. Harvey Kaufman, senior medical director at Quest Diagnostics, and his colleagues analyzed data from Quest Diagnostics’ corporate database of clinical laboratory services for the first 6 months of 2013 and the same period in 2014, identifying 215,398 with a new diagnosis of diabetes in 2013 and 218,890 in 2014. A total of 26,237 were enrolled in Medicaid in 2013 vs. 29,673 in 2014 – a 13% increase in overall new diagnoses of diabetes.

©Tashatuvango/Thinkstockphotos.com

The increase was greater – 23% – in the 26 states and the District of Columbia that had expanded their Medicaid programs. In states that had not expanded, the increase in newly diagnosed patients was 0.4% (Diabetes Care 2015 March 23 [doi: 10.2337/dc14-2334]).

“It is likely that changes in access to health care for patients with Medicaid contributed to testing for diabetes at an earlier stage of disease,” Dr. Kaufman wrote .

Access to health care also identified patients at earlier stages of diabetes, as evidenced by diagnosis at a lower mean hemoglobin A1c level. In states with expanded Medicaid programs, mean HbA1c was 7.96 at diagnosis, compared to 8.14 in states without expanded Medicaid programs.

“These Medicaid patients with newly identified diabetes will experience better management of their diabetes than if diagnosis had been made later,” Dr.Kaufman wrote. “This could be anticipated to lead to fewer long-term complications.”

gtwachtman@frontlinemedcom.com

Recommended Reading

Type 2 diabetes lower in familial hypercholesterolemia
MDedge Internal Medicine
Achieving diabetes treatment goals rarely influenced by provider beliefs
MDedge Internal Medicine
Type 1 diabetes doubles infection and hospitalization risk
MDedge Internal Medicine
Statins for all eligible under new guidelines could save lives
MDedge Internal Medicine
CDC, AMA launch nationwide prediabetes awareness initiative
MDedge Internal Medicine
Long-acting basal insulins aim to reduce hypoglycemia
MDedge Internal Medicine
Apple’s ResearchKit
MDedge Internal Medicine
Weight gain after GDM linked to type 2 diabetes
MDedge Internal Medicine
ADA and EASD recommend improvements in monitoring insulin pump safety
MDedge Internal Medicine
Microbiome may drive the course of diabetes, obesity
MDedge Internal Medicine